Emerging targeted drug delivery strategies toward ovarian cancer

α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer

(2021) Zhe Wang et al.   Acta Biomaterialia

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

(2021) K.N. Moore et al.   ANNALS OF ONCOLOGY

Barriers to antibody therapy in solid tumors, and their solutions

(2021) Yasuhiro Matsumura   CANCER SCIENCE

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

(2020) David M. O'Malley et al.   GYNECOLOGIC ONCOLOGY

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

(2020) Emanuele Perrone et al.   Frontiers in Oncology

Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy

(2020) Quan Zhou et al.   BIOMATERIALS

Targeting Strategies for Tissue-Specific Drug Delivery

(2020) Zongmin Zhao et al.   CELL

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

(2020) Raffit Hassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer

(2020) Qingfei Zhang et al.   NANO LETTERS

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

(2020) Qianqian Pan et al.   ACS Biomaterials-Science & Engineering

Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation

(2020) Wenxing Gu et al.   JOURNAL OF CONTROLLED RELEASE

CA125 and Ovarian Cancer: A Comprehensive Review

(2020) Parsa Charkhchi et al.   Cancers

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

(2019) Michael J. Birrer et al.   ONCOLOGIST

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

(2019) Johann S de Bono et al.   LANCET ONCOLOGY

Epithelial ovarian cancer

(2019) Stephanie Lheureux et al.   LANCET

First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors

(2019) Ignacio Garrido-Laguna et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.

(2019) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer

(2019) Shu Li et al.   Drug Design Development and Therapy

Ligand density on nanoparticles: A parameter with critical impact on nanomedicine

(2019) Alaaldin M. Alkilany et al.   ADVANCED DRUG DELIVERY REVIEWS

HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor

(2019) Lin Ding et al.   BIOMACROMOLECULES

Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumors

(2019) Yu Yan et al.   ACS Applied Materials & Interfaces

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

(2019) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment

(2019) Xin Jin et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy

(2019) Marcela Tavares Luiz et al.   Materials Science & Engineering C-Materials for Biological Applications

Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer

(2018) Jiali Zhai et al.   ACS Applied Materials & Interfaces

Corrigendum to ‘Tumor-targeting peptides from combinatorial libraries’ [Adv Drug Deliv Rev.110–111 (2017) 13–37]

(2018) Ruiwu Liu et al.   ADVANCED DRUG DELIVERY REVIEWS

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

(2018) S Banerjee et al.   ANNALS OF ONCOLOGY

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo

(2018) Jie Li et al.   CANCER SCIENCE

Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer

(2018) Shan-Shan Hong et al.   DRUG DELIVERY

Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer

(2018) Pranali Deshpande et al.   DRUG DELIVERY

Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer

(2018) Ga Hee Kim et al.   DRUG DELIVERY

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

(2018) Kathleen N Moore et al.   Future Oncology

Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system

(2018) Gangliang Huang et al.   JOURNAL OF CONTROLLED RELEASE

GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment

(2018) Yan Zou et al.   MOLECULAR PHARMACEUTICS

Dual-targeted nanomedicines for enhanced tumor treatment

(2018) Yaqin Zhu et al.   Nano Today

Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer

(2018) Sophia A. Shahin et al.   Nanomedicine-Nanotechnology Biology and Medicine

Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer

(2018) Siva Sai Krishna Dasa et al.   Theranostics

Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial

(2018) Hai Wang et al.   ACS Central Science

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

(2018) Gururaj Shivange et al.   CANCER CELL

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

(2018) Kathleen N. Moore et al.   GYNECOLOGIC ONCOLOGY

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models

(2018) Maria Quanz et al.   Oncotarget

Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density

(2018) Clifford M. Csizmar et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

(2017) Lainie P. Martin et al.   GYNECOLOGIC ONCOLOGY

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

(2017) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Folate-mediated chemotherapy and diagnostics: An updated review and outlook

(2017) Leyuan Xu et al.   JOURNAL OF CONTROLLED RELEASE

RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery

(2017) Fengmei Pi et al.   Nanomedicine-Nanotechnology Biology and Medicine

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

(2017) Marc Damelin et al.   Science Translational Medicine

A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer

(2017) Fangfei Li et al.   Nature Communications

Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer

(2017) Rajesh Kotcherlakota et al.   Journal of Materials Chemistry B

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

(2017) R. W. Naumann et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation

(2016) Nick Cox et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

(2016) J. F. Liu et al.   ANNALS OF ONCOLOGY

Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics

(2016) Chun-Jui Lin et al.   BIOMATERIALS

Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer

(2016) Miriana Hijaz et al.   BMC CANCER

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target

(2016) Alfredo Perales-Puchalt et al.   CLINICAL CANCER RESEARCH

Precision targeted therapy of ovarian cancer

(2016) Justin Sapiezynski et al.   JOURNAL OF CONTROLLED RELEASE

Carboplatin-Complexed and cRGD-Conjugated Unimolecular Nanoparticles for Targeted Ovarian Cancer Therapy

(2016) Yuyuan Wang et al.   MACROMOLECULAR BIOSCIENCE

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

(2016) C. D. Weekes et al.   MOLECULAR CANCER THERAPEUTICS

Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

(2016) Lawrence J. Thomas et al.   MOLECULAR CANCER THERAPEUTICS

Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells

(2016) Hitesh Kulhari et al.   MOLECULAR PHARMACEUTICS

Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

(2016) Wenwu Xiao et al.   EJNMMI Research

Ovarian cancer

(2016) Ursula A. Matulonis et al.   Nature Reviews Disease Primers

Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance

(2015) Steven K. Jones et al.   BIOMACROMOLECULES

Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy

(2015) S. Das et al.   CANCER RESEARCH

Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers

(2015) K. Lin et al.   CLINICAL CANCER RESEARCH

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

(2015) M. Damelin et al.   CLINICAL CANCER RESEARCH

Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance

(2015) Liping Wang et al.   DRUG DELIVERY

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

(2015) Devansu Tewari et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

(2015) Andreas Wicki et al.   JOURNAL OF CONTROLLED RELEASE

IMGN853, a Folate Receptor-  (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors

(2015) O. Ab et al.   MOLECULAR CANCER THERAPEUTICS

Ovarian cancer: beyond resistance

(2015) David Holmes   NATURE

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer

(2015) Yan Gao et al.   Oncotarget

Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer

(2015) K. Urbanska et al.   Cancer Immunology Research

Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer

(2014) Srinivas Ganta et al.   DRUG DELIVERY

Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging

(2014) A. H. Maurer et al.   JOURNAL OF NUCLEAR MEDICINE

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models

(2014) S. J. Scales et al.   MOLECULAR CANCER THERAPEUTICS

Abstract 4628: Anti-tumor activity and pharmacokinetics of the anti-FOLR1-maytansinoid conjugate IMGN853 is maintained over a wide range of maytansinoid-to-antibody ratios

(2012) Kathleen R. Whiteman et al.   CANCER RESEARCH

"OA02" Peptide Facilitates the Precise Targeting of Paclitaxel-Loaded Micellar Nanoparticles to Ovarian Cancer In Vivo

(2012) K. Xiao et al.   CANCER RESEARCH

Canine malignant melanoma alpha-3 integrin binding peptides

(2011) Olulanu H. Aina et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

(2010) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

(2008) Angeles Alvarez Secord et al.   GYNECOLOGIC ONCOLOGY

Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid

(2008) Gianfranco Pasut et al.   JOURNAL OF CONTROLLED RELEASE